# SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases

> **NCT06787183** · PHASE2 · RECRUITING · sponsor: **Fujian Cancer Hospital** · enrollment: 42 (estimated)

## Conditions studied

- Locally Advanced Rectal Cancer With Liver Metastases

## Interventions

- **RADIATION:** Short course radiotherapy
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin
- **DRUG:** QL1706

## Key facts

- **NCT ID:** NCT06787183
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2026-12-01
- **Final completion:** 2029-12-01
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06787183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06787183, "SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT06787183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*